A test of safusidenib for IDH1-mutant glioma that grew during vorasidenib treatment
Original title: Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so the drug is not proven care yet.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called safusidenib in people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary grew while they were taking vorasidenib.
Who this trial is for. This trial is for people with a Grade 2 or Grade 3 glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has a change in the IDH1 gene. It is for people who had surgery and then took vorasidenib as their only treatment, and whose tumor grew on scans while on it. It plans to include up to 40 people, and it is testing a drug called safusidenib.
Where it stands. The trial has not reported results. It is set up to look at how safe safusidenib is and whether it helps. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you could ask your care team about it. They can tell you whether it fits your case. Safusidenib is still being tested, so it is not treatment your own doctor can simply give you.
What it doesn't mean: This does not mean safusidenib works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.